The most exciting company in Radiology AI is RevealDx. Our technology will significantly reduce lung cancer mortality through early diagnosis. We are coming off a successful launch in the EU, where we have already signed customers and significant reimbursement approvals are driving adoption.
We are now focusing on the US market, where demand for this technology is high and CMS reimbursement is already approved. To accomplish this we are raising seed capital from strategic and private investors to fund RevealDx through 2024.
In this presentation, we will present the clinical problem we are addressing and the impact we will have on patients. Next, we will review our product market fit and our go to market strategy. Lastly, we will review the investment thesis, team, and why this investment opportunity is unique. If you are considering investment, there will be an optional due diligence session at the end to review the specifics of the deal terms, risks, forecast and exit strategy.
We are looking for angel investors who understand the role of AI in healthcare. Physicians and business leaders in radiology, pulmonology and oncology are especially well positioned to appreciate the value our company brings. You do not need angel investment experience.*
Data shows that investing in a company you understand is the best opportunity to maximize the return on your investment. A study from Willamette University showed that investment multiples can be twice as high for investments in companies connected to an investor’s industry expertise.
While investing in early stage companies should not account for the bulk of your portfolio, it provides diversification outside of the public markets and real estate. This is an opportunity to invest in a market you understand and in a company that has already shown potential to maximize return for its early investors.
*You must meet certain financial thresholds to invest.
